- Home
- BRKH vs SKYE Comparison
BRKH vs SKYE Comparison
Compare BRKH & SKYE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BRKH
- SKYE
- Stock Information
- Founded
- BRKH 2021
- SKYE 2012
- Country
- BRKH United States
- SKYE United States
- Employees
- BRKH N/A
- SKYE N/A
- Industry
- BRKH Blank Checks
- SKYE Biotechnology: Pharmaceutical Preparations
- Sector
- BRKH Finance
- SKYE Health Care
- Exchange
- BRKH Nasdaq
- SKYE Nasdaq
- Market Cap
- BRKH 170.6M
- SKYE 172.9M
- IPO Year
- BRKH 2021
- SKYE N/A
- Fundamental
- Price
- BRKH $11.25
- SKYE $5.24
- Analyst Decision
- BRKH
- SKYE Strong Buy
- Analyst Count
- BRKH 0
- SKYE 5
- Target Price
- BRKH N/A
- SKYE $18.40
- AVG Volume (30 Days)
- BRKH 31.6K
- SKYE 142.7K
- Earning Date
- BRKH 01-01-0001
- SKYE 11-09-2024
- Dividend Yield
- BRKH N/A
- SKYE N/A
- EPS Growth
- BRKH N/A
- SKYE N/A
- EPS
- BRKH N/A
- SKYE N/A
- Revenue
- BRKH N/A
- SKYE N/A
- Revenue This Year
- BRKH N/A
- SKYE N/A
- Revenue Next Year
- BRKH N/A
- SKYE N/A
- P/E Ratio
- BRKH N/A
- SKYE N/A
- Revenue Growth
- BRKH N/A
- SKYE N/A
- 52 Week Low
- BRKH $10.48
- SKYE $1.44
- 52 Week High
- BRKH $11.28
- SKYE $19.41
- Technical
- Relative Strength Index (RSI)
- BRKH 59.44
- SKYE 42.33
- Support Level
- BRKH $11.12
- SKYE $5.71
- Resistance Level
- BRKH $11.24
- SKYE $7.11
- Average True Range (ATR)
- BRKH 0.01
- SKYE 0.60
- MACD
- BRKH -0.00
- SKYE -0.08
- Stochastic Oscillator
- BRKH 48.39
- SKYE 10.00
About BRKH BurTech Acquisition Corp.
BurTech Acquisition Corp is a blank check company.
About SKYE Skye Bioscience Inc. Common Stock
Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. The company's clinical assets focus on the modulation of cannabinoid receptor 1 ("CB1") to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis and neurodegeneration, such as obesity and glaucoma. The company's Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, currently being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion ("SBI-100 OE"), a CB1 agonist (activator), currently being developed for the treatment of glaucoma and ocular hypertension.